Literature DB >> 2984325

Comparison of Western Blot Analysis to microneutralization for the detection of type-specific herpes simplex virus antibodies.

D I Bernstein, E Garratty, M A Lovett, Y J Bryson.   

Abstract

A newly developed system (as described in the previous paper) employing separated herpes simplex virus (HSV) polypeptides electrophoretically transferred to nitrocellulose paper, Western Blot Analysis (WBA), was compared to microneutralization (MN) for the detection of type-specific antibody to HSV types 1 and 2 in 98 human sera. Sera containing HSV1-specific antibodies reacted at least twofold more densely (as quantitated by densitometric scanning) to HSV1 than HSV2 polypeptides, while sera with HSV2-specific antibodies reacted twofold more densely to HSV2 polypeptides. The reliability of this system was determined (1) by analysis of sera from patients with true primary herpes simplex infections, (2) by adsorption studies that removed cross-reacting antibodies, and (3) by comparison with neutralization. Of 36 sera found to have HSV1-type-specific antibody by WBA, 83% had MN ratios of less than 85 (indicating HSV1 antibody), while of 28 sera found to have HSV2-type-specific antibody by WBA, 89% had MN ratios of greater than 85 (indicating HSV2 antibodies). The MN ratio obtained on sera felt to have both HSV1-type-specific and HSV2-type-specific antibody by WBA ranged from 67 to 160. WBA agreed more closely with clinical isolates and adsorption studies than MN. This system not only accurately determines the HSV-type-specific antibody status of patients but provides important information on the specific immunogenic proteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984325     DOI: 10.1002/jmv.1890150303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Occupational risk of HIV, HBV and HSV-2 infections in health care personnel caring for AIDS patients.

Authors:  T L Kuhls; S Viker; N B Parris; A Garakian; J Sullivan-Bolyai; J D Cherry
Journal:  Am J Public Health       Date:  1987-10       Impact factor: 9.308

2.  Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.

Authors:  J Kahlon; F D Lakeman; M Ackermann; R J Whitley
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

3.  Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences.

Authors:  M J Levin; F N Judson; L Eron; Y J Bryson; L Corey; M Murray; R R Scheer
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.